Taikang Insurance Group Company

Taikang Insurance Group was established in 1996 and is headquartered in Beijing. It has developed into a large insurance financial service group covering insurance, asset management, and medical care. Taikang Insurance Group owns Taikang Life Insurance, Taikang Assets, Taikang Pension, Taikang Jiantou, Taikang Health, Taikang Online, and other subsidiaries. The business scope covers a wide range of areas including life insurance, Internet property insurance, enterprise annuity, asset management, medical pension, health management, and commercial real estate. As of the end of 2017, the assets under management exceeded RMB 1.2 trillion. Since its establishment 22 years ago, the Group has provided a total of 225 million customer service customers and over 340,000 service enterprise customers. The accumulated payment of claims amounted to 35.1 billion yuan and accumulated tax payment of 37.5 billion yuan. It has been ranked among the “Top 500 Chinese Enterprises” for 14 consecutive years. In 2018, Taikang Insurance Group ranked No. 489 in the Fortune Global 500 list with an operating income of US$24.085 billion, marking Taikang's entry into the ranks of the world's largest insurance financial services group. Taikang Insurance Group has always adhered to the concept of “professionalization, marketization, and standardization”, and has deepened the life insurance industry chain. Through 3,900 offline physical networks, online internet platforms and 700,000 employees and salesmen across the country, relying on “vigorous pension, The four-in-one business model of high-end medical care, excellent financial management, and ultimate care builds a healthy ecosystem of the big health industry. Committed to becoming the world's leading insurance financial services group, making insurance more secure, more convenient and more affordable, making people healthier, longer life and richer, making Taikang a part of people's happy life. Taikang Insurance Group integrates the whole life industry chain through the cross-border integration of virtual insurance products and physical medical services to implement a healthy China strategy. As the first pilot enterprise in China's insurance industry to invest in old-age care communities, the Group has completed the layout of pension communities in key cities such as Beijing, Shanghai, Guangzhou, Sanya, Suzhou, Chengdu, Wuhan, Hangzhou, Nanchang, Xiamen, Shenyang and Changsha, becoming the largest in the country. One of the high quality chain pension groups. Adhering to the concept of medical integration, the rehabilitation community with rehabilitation and geriatrics is built in the old-age community to build a Taikang international standard rehabilitation system. At present, the Group has invested in the operation of Taikang Xianlin Drum Tower Hospital, the construction of Taikang Tongji (Wuhan) Hospital, the launch of Taikang Southwest Medical Center, and efforts to build a number of medical education and research integrated medical centers. Taikang Insurance Group adheres to the concept of “serving the public and giving back to the society” and actively fulfills its corporate social responsibility. Especially in the fields of education and academics, a comprehensive education donation system has been formed from primary schools, middle schools, universities to China's economic theory innovation awards. Through the non-profit art organization “Tai Kang Space”, it sponsored and supported the development and research of Chinese contemporary art, and launched “Yi Cai”. The Public Welfare Program continues to support life and big health charity initiatives, and we donate to the nursing homes throughout the country to let more elderly people enjoy their happy and happy years. At present, the personal donation amount of the group and Chairman Chen Dongsheng has reached 430 million yuan.

25 past transactions

Singularity Cloud

Series C in 2022
Singularity Cloud is a tech company focused on using big data and AI technology to enhance the business capabilities of enterprises.

ClinChoice昆翎

Series E in 2022
ClinChoice Kunling was established in Tianjin inSince its establishment, through its own organic growth and strategic mergers and acquisitions, ClinChoice has more than 3,000 clinical R&D professionals around the world, located in hot cities and regions of domestic and foreign pharmaceutical R&D, and has developed into a local clinical CRO enterprise model supporting innovative drug device R&D. . The company adheres to the connotation of "Kunxing Zhiyuan · Ling creates the future", which means to become an ideal partner for the clinical research and development of innovative pharmaceutical devices.

UINO

Series C in 2022
UINO provides real-time digital twin visualization software to manage digital infrastructures. The company manages to combine digital twin technology and visualization to create a complete digital representation of physical objects in the real world. Through digital twin visualization technology, it helps people better understand and manage the real world by simulating, monitoring, analyzing, and controlling physical objects. It connects the logical world and the physical world across the digital space.

XISOFT

Series B in 2022
XISOFT is a professional manufacturer of informatization and data services in the field of health economic management. XISOFT is dedicated to using technology and services to assist medical institutions by providing a smart operations management tool. It fully supports the strategic implementation of medical institutions and realizes business integration and refined management by covering intelligent finance, material assets, internal control, human resources, comprehensive management, event management, data services, information platforms, and so on.
Hong Kong Asia Heart Centre is a cardiovascular specialist chain that provides various cardiovascular assessment and surgical services. Founded in 1999, The Hong Kong Asian Heart Center has a professional medical team with many years of experience in the treatment of heart disease.

Singularity Cloud

Series C in 2021
Singularity Cloud is a tech company focused on using big data and AI technology to enhance the business capabilities of enterprises.

Star Charge

Series B in 2021
Star Charge focuses on developing and manufacturing the new energy vehicle charging equipment.

XINGYUN GROUP

Series C in 2021
Xingyun Group has reconstructed the digital supply chain in consumer goods. It empowers the global commodity trade environment through whole-process SaaS tools, and provides one-stop, full-category, Direct-to-consumer (DTC) digital supply chain services in consumer goods. The Management Middle-end System Services Engine of Xingyun Global Supply Chain focuses on the integration of industrial ecological resources, enables cost reduction and efficiency improvement with industrial data, serves overseas consumer brands to enter China, helps Chinese brands go global, and empowers global supply chain and SaaS service capability of the platform for massive merchants. It has nearly 160 cooperative and self-operated warehouses in 72 countries and 1 region, serving more than 350,000 online and offline retailers in China.
Jihu Information Technology (Hubei) Co., Ltd. is referred to as GitLab, adhering to the "Open-core" principle, combining the world's leading DevOps technology with localized self-developed innovation and customized services, is committed to serving Chinese users. Provide a one-stop open and integrated DevOps platform covering the software development life cycle. Jihu GitLab owns the exclusive intellectual property rights and brand authorization of GitLab, Inc. It is updated monthly based on the GitLab EE version, and on this basis, we add our customized features for domestic users. JiHu GitLab is an out-of-the-box, open DevOps platform built from the ground up as a single application for all stages of the DevOps lifecycle enabling Product, Development, QA, Security, and Operations teams to work concurrently on the same project. JiHu GitLab provides a single data store, one user interface, and one permission model across the DevOps lifecycle, accelerating software development lifecycle through industry-leading project management, security, and compliance features. JiHu GitLab is independently developed and operated in China by GitLab Information Technology (Hubei) Co., Ltd. Investors include GitLab Inc., Sequoia CBC and Gaocheng Capital.

Dingdang Kuaiyao

Series B in 2020
Dingdang Kuaiyao is an online-to-offline drug purchasing and delivery platform. After users place orders on the mobile app, drugs will be delivered to their homes within half an hour.

XINGYUN GROUP

Series C in 2020
Xingyun Group has reconstructed the digital supply chain in consumer goods. It empowers the global commodity trade environment through whole-process SaaS tools, and provides one-stop, full-category, Direct-to-consumer (DTC) digital supply chain services in consumer goods. The Management Middle-end System Services Engine of Xingyun Global Supply Chain focuses on the integration of industrial ecological resources, enables cost reduction and efficiency improvement with industrial data, serves overseas consumer brands to enter China, helps Chinese brands go global, and empowers global supply chain and SaaS service capability of the platform for massive merchants. It has nearly 160 cooperative and self-operated warehouses in 72 countries and 1 region, serving more than 350,000 online and offline retailers in China.

ZongTeng Group

Series C in 2020
Fujian Zongteng Network Co., Ltd. provides warehouse and logistics services for e-commerce sellers. The company also operates export auto parts and household products business. It also offers warehousing and distribution, small-package logistics, transportation services and supply chain finance, and value added services for cross-border e-commerce companies. Fujian Zongteng Network Co., Ltd. was founded in 2007 and is based in Shenzhen, China. It has additional offices in Guangzhou and Shanghai, China and Monroe, New Jersey.

GKHT Medical Technology

Series C in 2019
Guoke Hengtai (Beijing) Medical Technology Co., Ltd. was established in February 2013 and is affiliated to Oriental Science and Technology Holding Group Co., Ltd. (hereinafter referred to as “Oriental Instrument”), a subsidiary of the State-owned Assets Supervision and Administration Commission of the Chinese Academy of Sciences. It is headquartered in Yizhuang Economic and Technological Development Zone, Beijing. . Since the establishment of Guoke Hengtai for 4 years, the company has experienced two rounds of investment in A and B, and its performance has continued to grow at a high speed, with a compound annual growth rate of over 50%. In 2017, the company officially launched the IPO listing journey.

Antengene Corporation

Series B in 2019
Antengene is a developer of biotechnology and bio-pharmaceuticals intended to provide medicine treatment for tumor.The company focuses on providing patients with innovative anti-tumor and anti-cancer therapies through new drug development, clinical research and drug production, enabling physicians to meet unmet medical needs in Asia.

Transcenta

Venture Round in 2019
Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture, focusing on developing innovative antibodies to help more patients. HJB and MabSpace Biosciences merged and created Transcenta.

Taikang Bybo Dental

Acquisition in 2018
Taikang Bybo Medical Group is a national dental medical group with a large-scale operation. It is dedicated to providing high-quality full-lifecycle oral medical services for middle and upper-income people, pursuing the ultimate customer experience, investigating the "Caesar model" in the field of domestic oral medical services, and constructing China's largest and best high-end dental chain brand.

CStone Pharmaceuticals

Series B in 2018
CStone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative tumor immunotherapy and precision treatment drugs to meet the intensive medical needs of cancer patients in China and around the world.CStone Pharmaceuticals has assembled a world-class management team with extensive experience in new drug development, clinical research, and commercialization. The company has built a rich product pipeline composed of 15 tumor candidate drugs with the combination of tumor immunotherapy as the core.

Innovent Biologics

Series E in 2018
Innovent Biologics, Inc. is a privately held biopharmaceutical company dedicated to developing and manufacturing monoclonal antibodies to be marketed in China and elsewhere around the world. Innovent is funded by Fidelity's venture arm, a prominent investment firm in the US, Lilly Ventures, and Suzhou bioBay. The registered capital is 30 million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development, and manufacture of biologics in the US, Europe, and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others.

Easyhome

Private Equity Round in 2018
Beijing Easyhome Home New Retail Chain Group Co., Ltd. is a prominent retail business based in China, specializing in home improvement and furniture. It operates 223 physical stores across 29 provinces, positioning itself as the second largest home furnishing and DIY chain in the country. In addition to its retail operations, Easyhome is involved in commercial property development and shopping mall decoration. The company also engages in e-commerce and owns various retail formats, including department stores, hypermarkets, and cheap supermarkets. Its diverse portfolio includes leasing and project development services, catering to a wide range of consumer needs in the home improvement sector.

EOC Pharma Group

Series B in 2017
EOC Pharma is an integrated biopharmaceutical company that is focused on the manufacturing, development and commercialization of innovative global oncology products in China. They have adopted a licensing model in order to build EOC’s innovative pipeline by plugging their partner’s molecule into EOC’s “core engine” of local manufacturing, clinical development, regulatory filing, and commercialization. The company has a pipeline of seven novel products from global biopharmaceutical partners that are potentially first- and best-in-class. Until now, EOC has obtained four Class I innovative drug CTA approvals and initiated clinical studies of four lead products in China.,EOC has a team of entrepreneurs and consultants with overseas background that boasts of first-class pharmaceutical R&D expertise as well as rich industry experience. The company owns an 8,000 square meter cGMP manufacturing facility in Taizhou, China Medical City and has offices in Shanghai, Beijing, Hong Kong and Los Angeles. EOC will leverage forward-looking licensing which will provide product opportunities to their integrated platform, generating a highly strategic portfolio. Ultimately, this will position EOC at the top of oncology innovation in China.
Hangzhou Just Biotherapeutics is a comprehensive high-tech design company dedicated to accelerating the development of bio-medicine and significantly reducing manufacturing costs. Their core strengths are molecular design, process design, drug product design and manufacturing plant design.

MXB Biotechnologies

Angel Round in 2017
MXB Biotechnologies is a company that develops immunohistochemical diagnostic reagents for tumor pathology. The scope of the company includes molecular pathological diagnosis, precision medical diagnostics, immunocytochemistry diagnosis, and tumor pathological diagnosis. The items are utilized for clinical diagnostics and pathology department diagnosis.

Innovent Biologics

Series D in 2016
Innovent Biologics, Inc. is a privately held biopharmaceutical company dedicated to developing and manufacturing monoclonal antibodies to be marketed in China and elsewhere around the world. Innovent is funded by Fidelity's venture arm, a prominent investment firm in the US, Lilly Ventures, and Suzhou bioBay. The registered capital is 30 million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development, and manufacture of biologics in the US, Europe, and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others.

Womai

Series C in 2015
Womai net is a B2C healthy food shopping website in China. It insists on providing customers with convenient shopping ways and purchase healthy food. Womai net was founded by World Top 500 Enterprises COFCO Corporation in 2008. The COFCO(COFCO) is China’s leading diversified products and services supplier of agricultural products and food field, which is committed to utilizing the constantly renewable natural resources to provide human with nutrient and healthy food, high quality life space and life service, and contribute to the prosperity of human society.

BGI Tech

Venture Round in 2015
BGI Tech Solutions Co., Ltd. (BGI-Tech), is a world leader in cutting-edge life sciences technology and premier scientific partner to the global research community. With a firm commitment to providing the highest quality services through our worldwide service network, BGI-Tech’s mission is to facilitate ground-breaking research, foster productive collaboration and accelerate scientific advancement. BGI-Tech was founded in 2012 and is headquartered in Shenzhen, China. BGI-Tech has lab facilities in Hong Kong, Wuhan (China),and Sacramento, California (United States). It also has branch offices in Europe, the Americas, Asia- Pacific, and in Beijing, Shanghai, and Guangzhou of mainland China. Its service network covers more than 100 countries and regions. Currently, BGI-Tech collaborates with over 10,000 organizations and 30,000 partners, providing highly reliable services for thousands of research projects, including several large-scale international genome projects. With diverse service experience, unique scientific expertise, BGI-Tech is committed to developing integrated omics platforms to revolutionize life science research, to accelerate the advancement of the life science industry and to address various health, agricultural, energy, and environmental issues to improve life and society.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.